MaxCyte, Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
MaxCyte is a life sciences company providing cell-engineering platforms, instruments, processing assemblies, consumables and related licenses to cell-therapy, drug-discovery and biomanufacturing customers. The filing covers the three and six months ended June 30, 2023, compared with the corresponding 2022 periods.
Key financial metrics
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $9.0 million | $9.6 million | $17.6 million | $21.2 million |
| Gross profit | $7.7 million | $8.5 million | $15.2 million | $19.0 million |
| Gross margin | 85% | 88% | 87% | 90% |
| Operating loss | $13.1 million | $8.7 million | $26.3 million | $12.9 million |
| Net loss | $10.5 million | $8.3 million | $21.4 million | $12.3 million |
| Loss per share | $0.10 | $0.08 | $0.21 | $0.12 |
| Net cash used in operating activities | Not provided for the quarter | Not provided for the quarter | $14.4 million | $2.8 million |
Q2 revenue declined 6% year over year, while six-month revenue declined 17%. Q2 revenue included $6.6 million from cell therapy, $1.7 million from drug discovery and $0.8 million of program-related revenue. Six-month revenue included $12.6 million, $3.5 million and $1.6 million, respectively.
As of June 30, 2023, cash and cash equivalents were $54.6 million and short-term investments were $161.6 million, for total cash and short-term investments of $216.1 million. Total assets were $271.2 million, total liabilities were $30.2 million and stockholders’ equity was $241.0 million. The company reported no debt obligations.
Material changes versus the prior comparable period
- Q2 revenue decreased $0.6 million, or 6%, primarily because of lower cell-therapy and drug-discovery instrument and disposable sales; the decline was partly offset by higher milestone revenue.
- Six-month revenue decreased $3.6 million, or 17%, due to lower cell-therapy revenue of $2.5 million, lower drug-discovery revenue of $0.6 million and lower program-related revenue of $0.5 million.
- Gross margin declined to 85% in Q2 and 87% for the six-month period, versus 88% and 90%, respectively, primarily because of higher initial costs from scaling in-house processing-assembly manufacturing.
- Q2 operating expenses increased 20% to $20.7 million. Research and development rose 21%, sales and marketing rose 31%, general and administrative expense rose 8%, and depreciation and amortization rose 97%.
- Six-month operating expenses increased 30% to $41.5 million, reflecting continued investments in research and development, commercial staffing, product development, facilities and public-company infrastructure.
- Interest income increased to $2.6 million in Q2 and $4.9 million for the six-month period, driven by higher interest rates and larger interest-bearing balances.
- Net cash used in operations increased to $14.4 million for the first six months, compared with $2.8 million in the prior-year period. Investing activities provided $56.3 million, primarily from maturities of short-term investments.
Guidance, outlook, commentary and risks
The company did not provide a specific quantitative revenue or earnings forecast in the filing. Management expects revenue to increase over time as customer programs advance, markets grow, installed-base licenses expand and additional Strategic Platform License agreements are signed. Management also expects revenue and milestone timing to remain variable.
Management expects continued near-term operating losses and increased research and development, sales and marketing, general and administrative and product-development spending. It believes existing cash and short-term investments will fund operating expenses and capital requirements for the foreseeable future, but notes that this assessment depends on assumptions that may prove incorrect.
- Program-related milestone revenue is inherently variable and dependent on customers’ clinical progress and commercialization decisions.
- Customer purchasing timing, availability of capital to biotechnology customers and market adoption of non-viral cell-engineering approaches may affect revenue.
- Initial in-house manufacturing costs are elevated due to lower utilization; management expects costs to improve with utilization, experience and automation.
- The company faces competition from alternative cell-engineering technologies, including potential GMP-grade competing platforms that could pressure pricing and margins.
- Two customers represented 27% of Q2 revenue and 30% of six-month revenue. One supplier represented 49% of Q2 inventory purchases and 55% of six-month purchases.
- The company had $16.2 million of operating lease liabilities recorded and approximately $29.6 million of incremental non-cancellable lease payments through August 2035. Phase 3 of its headquarters lease was expected to begin in the second half of 2023.
- Management reported no material legal proceedings and no material changes to the risk factors disclosed in the 2022 Form 10-K.
Important facts for investors to verify
- Whether cell-therapy and drug-discovery instrument and consumables revenue reaccelerates after the reported purchasing-timing effects.
- The pace, size and timing of new Strategic Platform License agreements and associated milestone revenue.
- Whether in-house manufacturing achieves expected utilization and margin improvements.
- Operating cash burn, investment balances and the expected duration of available liquidity as operating losses continue.
- Customer and supplier concentration, including the potential impact of losing a major customer or experiencing supply disruption.
- The effect of continued hiring, stock-based compensation and research and commercial investments on the path to profitability.